FDA approves Gilead's triple combo HIV therapy

Gilead Sciences Inc. (NASDAQ:GILD) said FDA approved Biktarvy bictegravir/emtricitabine/tenofovir alafenamide to treat HIV-1 infection. Gilead told BioCentury it plans to launch the drug this week at a wholesale acquisition cost (WAC) of $2,945.65 for a 30-tablet bottle, or $35,839 for a 12-month supply.

Biktarvy is indicated for adults with no prior history of antiretroviral treatment or as a replacement in virologically suppressed adults on a stable regimen for at least three months with no history or treatment failure or resistance to the individual components of Biktarvy...